Ation this mutation is extremely rare. Reports about ASE of both BRCA1 and BRCA2 to be associated with increased breast cancer risk [14] indicated that in some of the cases, ASE could be explained by mutations activating the nonsense mediated mRNA decay. In the majority of cases, however, 1081537 ASE remained mechanistically Tunicamycin web unexplained. In a report implicating the association of CDH1 ASE with hereditary diffuse gastric cancer [35], one ASE-positive proband showed an unusual pattern of allele-specific methylation in the promoter. To elucidate the potential mechanisms of DAPK1 ASE in CLL, we investigated a CLL-related leukemic cell line model. Prompted by the observation of extensive 58-49-1 site Epigenetic silencing by DNA methylation of DAPK1 in the clonal malignant B cells of CLL patients, we hypothesized a role for an underlying epigenetic cause of ASE in the non-malignant (germline) cells. In contrast to the previously reported unidirectional expression imbalances of TGFBR1, DAPK1 ASE was found to be bi-directional implicating shifts to either allele. This could support the role of DNA methylation as underlying silencing event potentially induced from a different locus in trans. In Granta-519 cells, which showed a pronounced allelic mRNA expression imbalance without any copy number variations in the region of the DAPK1 gene, promoter DNA methylation levels of approximately 50 were observed. An allele-specific distribution of DNA methylation was associated with the repressed allele. Furthermore, we could show that after erasure of DNA methylation at this locus by a DNA hypomethylating agent, re-establishment of ASE occurred exclusively at the initially repressed allele. This indicates that epigenetic mechanisms could cause ASE of DAPK1 in CLLrelevant cell line models. We postulated an underlying genetic mutation as a cause for the allelic restriction of DNA methylation in ASE-positive Granta-519. However, sequencing up to approximately 6 kb upstream of DAPK1 TSS did not reveal any genetic variation. Similarly, we analyzed germline material from ASEpositive patients for allele-specific epigenetic marks and used patients with perfect allelic balance as control. We could not detect any genetic aberrations in the DAPK1 59 upstream regulatory region. Interestingly, we observed significantly elevated DNA methylation in ASE-positive cases around the transcriptional start site, which is in concordance with ASM observed in Granta-519 cells and might point towards an epigenetic cause for ASE. The primary genetic basis might act in trans far from the target and may be difficult to detect. However, the methylation differences were subtle and it remains mechanistically unclear how these differences are established and whether they might be causative for ASE. Epigenetic mechanisms have the potential of modulating gene expression, but so far they have not been thoroughly investigated as a potential mechanism for ASE. Exceptions 18334597 are epimutations identified in MLH1 or MSH2 leading to gene silencing and predisposition in hereditary forms of colorectal cancer [23]. For some of these epimutations, genetic alterations have been described that can trigger epigenetic events. For example, it has been shown that heterozygous germline deletions of the last exon of TACSTD1, a gene directly upstream of MSH2, resulted in extension of the transcription into the promoter of MSH2, thereby triggering by an unknown mechanism subsequent epigenetic alteration of the MSH2 promoter [36]. Cu.Ation this mutation is extremely rare. Reports about ASE of both BRCA1 and BRCA2 to be associated with increased breast cancer risk [14] indicated that in some of the cases, ASE could be explained by mutations activating the nonsense mediated mRNA decay. In the majority of cases, however, 1081537 ASE remained mechanistically unexplained. In a report implicating the association of CDH1 ASE with hereditary diffuse gastric cancer [35], one ASE-positive proband showed an unusual pattern of allele-specific methylation in the promoter. To elucidate the potential mechanisms of DAPK1 ASE in CLL, we investigated a CLL-related leukemic cell line model. Prompted by the observation of extensive epigenetic silencing by DNA methylation of DAPK1 in the clonal malignant B cells of CLL patients, we hypothesized a role for an underlying epigenetic cause of ASE in the non-malignant (germline) cells. In contrast to the previously reported unidirectional expression imbalances of TGFBR1, DAPK1 ASE was found to be bi-directional implicating shifts to either allele. This could support the role of DNA methylation as underlying silencing event potentially induced from a different locus in trans. In Granta-519 cells, which showed a pronounced allelic mRNA expression imbalance without any copy number variations in the region of the DAPK1 gene, promoter DNA methylation levels of approximately 50 were observed. An allele-specific distribution of DNA methylation was associated with the repressed allele. Furthermore, we could show that after erasure of DNA methylation at this locus by a DNA hypomethylating agent, re-establishment of ASE occurred exclusively at the initially repressed allele. This indicates that epigenetic mechanisms could cause ASE of DAPK1 in CLLrelevant cell line models. We postulated an underlying genetic mutation as a cause for the allelic restriction of DNA methylation in ASE-positive Granta-519. However, sequencing up to approximately 6 kb upstream of DAPK1 TSS did not reveal any genetic variation. Similarly, we analyzed germline material from ASEpositive patients for allele-specific epigenetic marks and used patients with perfect allelic balance as control. We could not detect any genetic aberrations in the DAPK1 59 upstream regulatory region. Interestingly, we observed significantly elevated DNA methylation in ASE-positive cases around the transcriptional start site, which is in concordance with ASM observed in Granta-519 cells and might point towards an epigenetic cause for ASE. The primary genetic basis might act in trans far from the target and may be difficult to detect. However, the methylation differences were subtle and it remains mechanistically unclear how these differences are established and whether they might be causative for ASE. Epigenetic mechanisms have the potential of modulating gene expression, but so far they have not been thoroughly investigated as a potential mechanism for ASE. Exceptions 18334597 are epimutations identified in MLH1 or MSH2 leading to gene silencing and predisposition in hereditary forms of colorectal cancer [23]. For some of these epimutations, genetic alterations have been described that can trigger epigenetic events. For example, it has been shown that heterozygous germline deletions of the last exon of TACSTD1, a gene directly upstream of MSH2, resulted in extension of the transcription into the promoter of MSH2, thereby triggering by an unknown mechanism subsequent epigenetic alteration of the MSH2 promoter [36]. Cu.